Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Prostatic Neoplasms 5Carcinoma, Hepatocellular 4Parathyroid Neoplasms 2Multiple Endocrine Neoplasia Type 1 1Liver Diseases 1Hyperparathyroidism, Primary 1Disease 1Breast Neoplasms 1

Interventions

Fulvestrant 5Exercise 5Eating 5Standard of Care 3Sodium Chloride 3Diet 3Alpelisib 3ribociclib 2gallium Ga 68 dotatate 2exemestane 2Vitamin D 2Tamoxifen 2Magnetic Resonance Spectroscopy 2Letrozole 2Ethanol 2Blood Specimen Collection 2Anastrozole 2zopiclone 1ziprasidone 1veliparib 1testosterone undecanoate 1testosterone enanthate 1pazopanib 1mirabegron 1methyl hydroxyethyl cellulose 1lenvatinib 1fluorocholine 1evolocumab 1dimethandrolone-undecanoate 1cyclopropapyrroloindole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Endocrine Neoplasia Type 1 × fluorocholine × Clear all
NCT07444723 2026-05-12

Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors

National Institutes of Health Clinical Center (CC)

Phase 2/3 Recruiting
193 enrolled
EndocrineHead & Neck

Parathyroid Neoplasms, Multiple Endocrine Neoplasia Type 1, Hyperparathyroidism, Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡